Abstract:OBJECTIVETraumatic brain injury (TBI) is a major cause of long-term disability and death in young adults. The lack of pharmaceutical therapy for post-acute TBI recovery remains a crucial medical challenge. Stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF), which are 2 key hematopoietic growth factors, have shown neuroprotective and neurorestorative effects in experimental stroke. The objective of this study was to determine the therapeutic efficacy of combined treatment (SCF + G-CSF) in subacute TBI.METHODSYoung-adult male C57BL mice were subject to TBI in the cortex of the right hemisphere. After TBI induction, mice were randomly divided into 2 groups: a vehicle control group and an SCF + G-CSF treatment group. Mice without TBI served as sham operative controls. Treatment was initiated 2 weeks after TBI induction. SCF (200 μg/kg) and G-CSF (50 μg/kg) or an equal volume of vehicle solution was subcutaneously injected daily for 7 days. A battery of neurobehavioral tests for evaluation of memory and cognitive function (water maze and novel object recognition tests), anxiety (elevated plus maze test), and motor function (Rota-Rod test) was performed during the period of 2-9 weeks after treatment. Neurodegeneration and dendritic density in both hemispheres were determined through histochemistry and immunohistochemistry at 11 weeks posttreatment.RESULTSWater maze testing showed that TBI-impaired spatial learning and memory was restored by SCF + G-CSF treatment. The findings from the elevated plus maze tests revealed that SCF + G-CSF treatment recovered TBI-caused anxiety and risk-taking behavior. There were no significant differences between the treated and nontreated TBI mice in both the Rota-Rod test and novel object recognition test. In the brain sections, the authors observed that widespread degenerating neurons were significantly increased in both hemispheres in the TBI-vehicle control mice. TBI-induced increases in neurodegeneration were significantly reduced by SCF + G-CSF treatment in the contralateral hemisphere, making it no different from that of the sham controls. Dendritic density in the frontal cortex of the contralateral hemisphere was significantly reduced in the TBI-vehicle control mice, whereas SCF + G-CSF-treated TBI mice showed significant increases of the dendritic density in the same brain region. SCF + G-CSF-treated TBI mice also showed a trend toward increasing dendritic density in the contralateral hippocampus.CONCLUSIONSSCF + G-CSF treatment in the subacute phase of TBI restored TBI-impaired spatial learning and memory, prevented posttraumatic anxiety and risk-taking behavior, inhibited TBI-induced neurodegeneration, and enhanced neural network remodeling. These findings suggest the therapeutic potential of hematopoietic growth factors for brain repair in the subacute phase of TBI.

Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline

High-frequency repetitive transcranial magnetic stimulation for treating moderate traumatic brain injury in rats: A pilot study

Combination Treatment With N-Acetyl-Seryl-Aspartyl-Lysyl-Proline and Tissue Plasminogen Activator Provides Potent Neuroprotection in Rats After Stroke

Neuroprotective Effects of Resatorvid Against Traumatic Brain Injury in Rat: Involvement of Neuronal Autophagy and TLR4 Signaling Pathway

TAK-242, a Toll-Like Receptor 4 Antagonist, Against Brain Injury by Alleviates Autophagy and Inflammation in Rats

Inhibition of Cathepsin S Produces Neuroprotective Effects after Traumatic Brain Injury in Mice

Intranasal Delivery of Cell-Penetrating Therapeutic Peptide Enhances Brain Delivery, Reduces Inflammation, and Improves Neurologic Function in Moderate Traumatic Brain Injury

Brain repair by hematopoietic growth factors in the subacute phase of traumatic brain injury

MMP-9 Inhibitor SB-3CT Attenuates Behavioral Impairments and Hippocampal Loss after Traumatic Brain Injury in Rat.

Self-assembling Peptide Nanofiber Scaffold Promotes the Reconstruction of Acutely Injured Brain.

Scriptaid, a Novel Histone Deacetylase Inhibitor, Protects Against Traumatic Brain Injury Via Modulation of PTEN and AKT Pathway

Intranasally Delivered Wnt3a Improves Functional Recovery After Traumatic Brain Injury By Modulating Autophagic, Apoptotic, And Regenerative Pathways In The Mouse Brain

Neuroprotective Effects of NAAG Peptidase Inhibition on the Treatment of Traumatic Brain Injury

Vaccines for immunological defense against traumatic brain injury

Inhibition of Transforming Growth Factor Beta-Activated Kinase 1 Confers Neuroprotection after Traumatic Brain Injury in Rats

The Cysteine Protease Cathepsin B is a Key Drug Target and Cysteine Protease Inhibitors Are Potential Therapeutics for Traumatic Brain Injury

Improvement in cognitive dysfunction following blast induced traumatic brain injury by thymosin α1 in rats: Involvement of inhibition of tau phosphorylation at the Thr205 epitope

Cathepsin B gene deletion and cysteine protease inhibition are effective in a traumatic brain injury model

Enhancing neurogenesis after traumatic brain injury: The role of adenosine kinase inhibition in promoting neuronal survival and differentiation

Inhibiting Endogenous Tissue Plasminogen Activator Enhanced Neuronal Apoptosis and Axonal Injury after Traumatic Brain Injury

Improvement in edema and cognitive recovery after moderate traumatic brain injury with the neurosteroid prodrug NTS-104